36603-49-3

Basic information

• Product Name: 2-(4-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN
• Synonyms: 2-(4'-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN;2-(4-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN;2-(4'-BROMOPHENOXY)-TETRAHYDROPYRAN;2-(4-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN, 9 8%;2-(4-Bromophenoxy)-pyran ;4-Bromophenyl THP ether;p-(2-Tetrahydropyranyloxy)phenyl bromide;p-(Tetrahydropyranyloxy)phenyl bromide
• CAS NO: 36603-49-3
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.12
• EINECS: 917-304-2
• Product Categories: Bromine Compounds;Miscellaneous Compounds;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyrans;PyransHeterocyclic Building Blocks;Building Blocks;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridines ,Halogenated Heterocycles
• Mol File: 36603-49-3.mol

Chemical Properties

• Melting Point: 56-58 °C(lit.)
• Boiling Point: 329.8 °C at 760 mmHg
• Flash Point: 147.9 °C
• Appearance: /
• Density: 1.403 g/cm³
• Vapor Pressure: 0.000332mmHg at 25°C
• Refractive Index: 1.553
• Storage Temp.: 2-8°C
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2-(4-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN(36603-49-3)
• EPA Substance Registry System: 2-(4-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN(36603-49-3)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 36603-49-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Bromophenoxy)tetrahydro-2H-pyran is used as a pharmaceutical intermediate for the production of various drugs. Its unique structure allows for the synthesis of a wide range of pharmaceutical compounds with potential therapeutic applications.
Used in Organic Synthesis:
2-(4-Bromophenoxy)tetrahydro-2H-pyran is used as a starting material in the synthesis of other complex organic compounds, such as 2-(4-lithiophenoxy)-tetrahydro-2H-pyran and 4-(tetrahydropyranyloxymethyl)phenyl magnesium bromide. These compounds can be further utilized in the development of new drugs and other chemical products.
Used in Chemical Production:
2-(4-Bromophenoxy)tetrahydro-2H-pyran can be used to produce 4-bromo-phenol at a temperature of 20°C. This chemical is an important intermediate in the production of various industrial chemicals and materials.

InChI:InChI=1/C11H13BrO2/c12-9-4-6-10(7-5-9)14-11-3-1-2-8-13-11/h4-7,11H,1-3,8H2

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 106-41-2 4-bromo-phenol 
• 24057-28-1 pyridinium p-toluenesulfonate 

Downstream Products

• 89598-97-0 (5-bromo-2-hydroxyphenyl)boronic acid 
• 133612-25-6 (Z)-2-<4-(2-hydroxy-1-methylethyl)phenyl>-1-(4-hydroxyphenyl)-1-<4-<2-(methylamino)ethoxy>phenyl>-1-butene 
• 133612-24-5 (E)-2-<4-(2-hydroxy-1-methylethyl)phenyl>-1-(4-hydroxyphenyl)-1-<4-<2-(methylamino)ethoxy>phenyl>-1-butene 
• 135247-72-2 (Z)-1-(4-hydroxyphenyl)-2-(4-isopropylphenyl)-1-<4-<2-(methylamino)ethoxy>phenyl>-1-butene hydrochloride 
• 135247-73-3 (E)-1-(4-hydroxyphenyl)-2-(4-isopropylphenyl)-1-<4-<2-(methylamino)ethoxy>phenyl>-1-butene hydrochloride 
• 115767-72-1 Miproxifene hydrochloride 
• 135272-48-9 (E)-1-<4-<2-(dimethylamino)ethoxy>phenyl>-1-(4-hydroxyphenyl)-2-(4-isopropylphenyl)-1-butene hydrochloride 
• 819060-13-4 7-Allyloxy-11-ethyl-10-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-10,11-dihydro-dibenzo[b,f]oxepin-10-ol 
• 819060-11-2 7-(2-Dimethylamino-ethoxy)-11-ethyl-10-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-10,11-dihydro-dibenzo[b,f]oxepin-10-ol 
• 100850-03-1 4-lithio tetrahydropyranyl phenol 
• 154423-56-0 1-{Hydroxy-phenyl-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-methyl}-naphthalen-2-ol 
• 103628-16-6 Z-1-<4-(2-chloroethoxy)phenyl>-1-(4-hydroxyphenyl)-2-phenyl-1-butene 
• 103628-17-7 E-1-<4-(2-chloroethoxy)phenyl>-1-(4-hydroxyphenyl)-2-phenyl-1-butene 
• 374898-49-4 (4-Benzyloxy-phenyl)-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-methanol 

Relevant articles and documents

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.

Cu-tethered macrocycle catalysts: Synthesis and size-selective CO2-fixation to propargylamines under ambient conditions

A novel air-stable, Cu-tethered macrocycle catalyst possessing a large inner cavity was successfully synthesized, creating a unique supramolecular catalytic system. The catalyst was utilized in the CO2-fixation reaction to propargylamines. The reaction proceeded more efficiently compared to the conventional CuI catalyst under atmospheric CO2 condition. Notably, owing to its topological effect, the Cu-tethered macrocycle catalyst exhibited unique substrate size selectivity.

Preparation method of 4-(4-hydroxyphenyl) cyclohexanone

The invention relates to the technical field of chemical synthesis, in particular to a preparation method of 4-(4-hydroxyphenyl) cyclohexanone. According to the preparation method, p-bromophenol is used as a raw material, a Grignard reagent is prepared through hydroxyl protection and Grignard reaction, then the prepared Grignard reagent is utilized to couple with 1,4-cyclohexanedione monoethyleneglycol ketal, then the product is dehydrated to obtain alkene, and double protecting groups are removed after hydrogenation to prepare a target product, namely, 4-(4-hydroxyphenyl) cyclohexanone. Thepreparation method of 4-(4-hydroxyphenyl) cyclohexanone, provided by the invention, has the advantages of reasonable process design, high yield and low production cost; the prepared 4-(4-hydroxyphenyl) cyclohexanone is a white solid, the HPLC content is more than 99.5%, the total yield of the product can reach 75-80%, and the raw materials are easy to obtain; and the method has simple operation and high safety, and realizes industrial production of 4-(4-hydroxyphenyl) cyclohexanone.

REACTIVE MESOGEN, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY COMPRISING THE SAME

The invention relates to a reactive mesogen, a liquid crystal composition and a liquid crystal display comprising the same. The reactive mesogen is represented by a chemical formula 1, wherein, X1 andX2 independently are hydrogen or halogen, Y is -O-, -S-

Phosphoramidate prodrug of nucleoside analogues, a pharmaceutical composition and applications of the phosphoramidate prodrug

The invention relates to phosphoramidate prodrug of nucleoside analogues, or stereoisomers of the phosphoramidate prodrug, or a mixture of the stereoisomers of the phosphoramidate prodrug, or pharmaceutically acceptable salts or solvates of the phosphoramidate prodrug, and applications in the preparation of medicine for preventing or treating hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV) infection alone or in combination with other medicine. The anti-HBV activity of the compound of the invention is equivalent to that of tenofovir alafenamide fumarate (TAF), and the compoundof the invention has the anti-liver fibrosis effect, can help improve the therapeutic effect of patients, and has good safety important clinical significance.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:wherein B is a nucleobase selected from the groups (a) to (d):and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

Cyclopropenium Enhanced Thiourea Catalysis

An integral part of modern organocatalysis is the development and application of thiourea catalysts. Here, as part of our program aimed at developing cyclopropenium catalysts, the synthesis of a thiourea-cyclopropenium organocatalyst with both cationic hydrogen-bond donor and electrostatic character is reported. The utility of the this thiourea organocatalyst is showcased in pyranylation reactions employing phenols, primary, secondary, and tertiary alcohols under operationally simple and mild reaction conditions for a broad substrate scope. The addition of benzoic acid as a co-catalyst facilitating cooperative Br?nsted acid catalysis was found to be valuable for reactions involving phenols and higher substituted alcohols. Mechanistic investigations, including kinetic and 1H NMR binding studies in conjunction with density function theory calculations, are described that collectively support a Br?nsted acid mode of catalysis.

Magnetic nanoparticle-supported DABCO tribromide: A versatile nanocatalyst for the synthesis of quinazolinones and benzimidazoles and protection/deprotection of hydroxyl groups

1,4-Diazabicyclo[2.2.2]octane tribromide supported on magnetic Fe3O4 nanoparticles (MNPs-DABCO tribromide) as a novel heterogeneous tribromide type compound was found to be an efficient and reusable nanocatalyst for the one-pot synthesis of 2-arylquinazolin-4(3H)-ones and 2-aryl-1H-benzo[d]imidazoles through oxidative cyclization of aldehydes with 2-aminobenzamides and 1,2-phenylenediamine, respectively. Also, MNPs-DABCO tribromide catalyzed trimethylsilylation/tetrahydropyranylation and desilylation/depyranylation of a wide variety of alcohols and phenols through changing the solvent medium at room temperature.

Zwitterionic imidazolium salt: An efficient organocatalyst for tetrahydropyranylation of alcohols

An aprotic imidazole based zwitterionic-salt, 4-(3-methylimidazolium)-butane sulfonate has been found to be an efficient organocatalyst for tetrahydropyranylation by the reaction of 3,4-dihydro-2H-pyran (DHP) and different aliphatic alcohols as well as various phenolic compounds. The notable advantages of the present method are general applicability to various alcohols, clean reaction, production of no hazardous waste, open air reaction conditions and high yields. The catalyst can be reused without the loss of significant catalytic activity.

Polymerizable compound optical element

PROBLEM TO BE SOLVED: To provide a polymerizable compound which has high solubility with a liquid crystal material and which has little amount of uncured monomers, high stability of a pretilt angle and hardly causes seizure when the compound is added to a liquid crystal material to manufacture a PSA (polymer sustained alignment) display element, and to provide a liquid crystal material containing the polymerizable compound.SOLUTION: The polymerizable compound is expressed by general formula (I). Further, a composition, a liquid crystal composition and an optical element including the compound are also provided.